IP Library Granted Patent US 7,943,379
Granted Patent B2
US 7,943,379 · App. 12/433,876 · Granted May 17, 2011

Production of rAAV in vero cells using particular adenovirus helpers

Assignee: Nationwide Children's Hospital, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,379
App. No.
12/433,876
Granted
May 17, 2011
Kind
B2
Abstract

The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).

Claims (21)

1. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of:

a) stably transforming a Vero cell with a rAAV genome and AAV rep/cap genes to generate a Vero producer cell,

b) infecting the Vero producer cell with simian adenovirus 13 (SAdV-13) helper virus and

c) culturing the Vero producer cell of step b) to produce rAAV.

2. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of:

a) stably transforming the Vero cell with AAV rep/cap genes to generate a Vero packaging cell,

b) introducing a rAAV genome into the Vero packaging cell,

c) infecting the Vero packaging cell of step b) with simian adenovirus 13 (SAdV-13) helper virus and

d) culturing the Vero packaging cell of step c) to produce rAAV.

3. The method of claim 2 , wherein the rAAV genome is introduced into the Vero packaging cell by infection with a rAd/AAV hybrid.

4. A method of producing infectious recombinant adeno-associated virus (rAAV) comprising the steps of:

a) introducing a rAAV genome and AAV rep/cap genes into a Vero cell,

b) infecting the Vero cell of step a) with simian adenovirus 13 (SAdV-13) helper virus and

c) culturing the Vero cell of step b) to produce rAAV.

5. The method of claim 4 wherein steps a) and b) occur concurrently.

6. The method of claim 4 wherein the Vero cell is a packaging cell.

7. The method of any of claims 1 - 6 further comprising the step of isolating the rAAV produced by the cell.

8. The method of claim 3 , wherein the Vero cell is infected with the rAd/AAV 16-24 hours after helper virus infection.

9. A method of producing infectious rAAV comprising culturing a Vero producer cell under conditions permissive for rAAV production, wherein the Vero producer cell comprises simian adenovirus 13 (SAdV-13) helper virus.

10. The method of any of claims 4 - 6 , 3 , wherein the SAdV-13 helper virus is SAdV-13 PME-12.

11. The method of 7 wherein the SAdV-13 helper virus is SAdV-13 PME-12.

Assignments (1)
CONFIRMATORY LICENSE Recorded Feb 23, 2010
From: CHILDREN'S HOSPITAL (COLUMBUS)
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023974/0656 →
Continuity (2)
Provisional Application 61049257 · Apr 30, 2008
Related Publication 20090275138A1 · Nov 5, 2009